The effect of Vitamin D on the prevention of statin associated muscle complications
Phase 3
- Conditions
- Acute ischemic heart disease.Acute ischemic heart disease, unspecified
- Registration Number
- IRCT20180513039645N1
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
All patients who have been recently treated with atorvastatin
Exclusion Criteria
Previous history of statin use
Previous history of Vitamin D Supplement use
having musculoscletal symptoms
history of musculoscletal disease
history of thyroid disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Statin associated muscle symptom score. Timepoint: At the beginning of the study, 1, 2 and 3 months after the start of taking statin and administering vitamin D and placebo. Method of measurement: Statin associated Muscle Symptom Score Questionnaire.;Serum Creatine Kinase level. Timepoint: At the beginning of the study and 3 months later. Method of measurement: By the laboratory.
- Secondary Outcome Measures
Name Time Method Cholesterol. Timepoint: At the beginning of the study and 3 months later. Method of measurement: By the laboratory.;Fasting blood sugar. Timepoint: At the beginning of the study and 3 months later. Method of measurement: By the laboratory.